CAS Insights^TM

Drug delivery across the blood-brain barrier has relied on passive diffusion of small-molecule drugs. A new CAS analysis shows that several other methods are having success in clinical development and could open new ways to treat conditions of the central nervous system.

The same protein can appear under many names across databases, leaving AI models with disconnected fragments instead of a unified biological context. See how authority constructs and biology ontologies give life sciences data a common language for more confident R&D decisions.

Organic light-emitting diodes have entered a phase of refinement rather than reinvention. A review of research and patent activity traces how a small set of recurring molecular motifs, stacked device architectures, and hybrid integration now drive performance, and why blue emitters remain the limiting factor.

Some discoveries are already latent in the published record, waiting for someone to read two literatures together. A look at why structured search and large language models each miss those connections, and what changes when AI reasons over verified scientific relationships rather than prose about them.

Treating mental health disorders has involved the same approach for nearly 70 years. Now, researchers are exploring new biological pathways and different potential drug compounds to better address conditions like depression, schizophrenia, and bipolar disorder.

Metamaterials are engineered structures that steer and absorb light, sound, and other waves in ways natural materials can’t. Our analysis of CAS data shows where they’re gaining ground, from consumer electronics to security and aerospace, and which materials lead the way.

Discover how Nobel-winning science unfolds—from breakthrough ideas to global recognition. CAS Insights reveals the context, challenges, and impact behind these discoveries.

Neuroinflammation is a known symptom of diseases like Alzheimer’s, Parkinson’s, and multiple sclerosis, but it’s also a driver in disease progression. This insight is leading to new therapeutic targets to reduce neuroinflammation.

Just as bio-based fuels and new technologies are changing Earth-based transportation, rocket propellants are also evolving to integrate sustainability, safety, and advanced materials engineering into chemical and non-chemical propulsion systems.

Digital initiatives are transforming the pharmaceutical industry, allowing for faster drug development and expanded treatment options.

Circularity is urgent to better address waste management challenges. Turning waste like used clothing and fibers into a strong, adaptable nanomaterial like nanocellulose is an important way to reduce landfill waste and create sustainable materials.

Five experts revisit their 2026 forecasts to ask: which predictions held up, which fell short, and what caught them by surprise?

Patent search looks like a retrieval problem, which is why general-purpose AI struggles with it. In a recent webinar, patent searchers and AI engineers explained where models fail when reading patent text, and what must sit underneath AI before its answers can be trusted.

Carbon dioxide is a greenhouse gas, but in its supercritical state it functions differently: as a non-toxic solvent that is biocompatible for use in pharmaceuticals, power generation, and more. Industrial applications are growing and are driving carbon sequestration efforts.

Genome AI language models wrote complete bacteriophage genomes from scratch, and 16 of the synthesized designs became viruses with antibacterial activity. A cocktail of those phages cleared E. coli strains that were resistant to the natural template phage.

Nanozymes are materials at the nanoscale that act like natural enzymes, but they’re more stable and can be tuned to have specific properties. While largely still in the research phase, these tiny catalysts could enable major breakthroughs in diagnostics, therapeutics, sensors, and environmental remediation.

Webinar recap: A patent-based analysis of where pharmaceutical innovation is heading, from diversifying therapeutic modalities and expanding molecular targets to the disease areas where research is accelerating.

Polymer science now spans millions of possible sequences and hundreds of billions in market value, making it harder than ever to spot what matters. A new joint report with PetroChina SAMRI maps the emerging topics shaping energy storage, sustainable materials, flexible electronics, and membranes.

Classical accuracy metrics assume one correct answer per question. Language models (LLMs) and agentic AI break that assumption. Learn about evaluation approaches emerging for scientific AI.

Deep eutectic solvents are key innovations for green chemistry. They’re cost-effective, environmentally friendly substances that can be used in drug delivery, wastewater treatment, and environmental clean-up. Researchers are finding new substances that make them more effective.

A first-of-its-kind data analysis of 25 years of published process chemistry reactions, conducted by CAS and Lilly, reveals long-term trends in solvents, catalysts, reaction conditions, and emerging methods at an industrial scale.

Immunotherapy is driving precision oncology, but existing immuno-oncology treatments aren’t effective for every patient. Our review of the translational research landscape reveals which targets and therapies are showing promising results in clinical trials.

AI tools are vital to patent searching, but they must have access to structured, indexed data to return reliable, comprehensive results.

2D materials like graphene and carbon nanotubes are revolutionizing materials science, and now MXenes are introducing even greater adaptability and high-performance properties. Find out why MXenes are versatile industrial materials.

Learn how composting has evolved into a precision-engineered bioprocess, and about how aeration, microbial control, materials science, and AI are reshaping the field.